Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.
Zhou HM, Zhang JG, Zhang X, Li Q. · 2021
Read Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. by Zhou HM, Zhang JG, Zhang X, Li Q. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7884707.txt.
Introduction
Zhou and co-authors present a review of cancer stem cells and resistance to therapy. Cancer stem cells can renew themselves and seed new tumour growth. Those traits help tumours survive treatment and come back. The review gathers what is known about how the resistance works.
The authors cover how these cells are identified in different tumours. They explain resistance that is built into the cells and resistance that comes from their surroundings. Key signalling pathways that let the cells ride out treatment are set out in turn. The review then surveys drugs and other agents aimed at these cells, from a clinical angle. It aims to guide new drug searches and better treatment plans. Readers see both the biology and the practical options.
Catalog record
| CREATOR | Zhou HM, Zhang JG, Zhang X, Li Q. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 124 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents By He-Ming Zhou, Ji-Gang Zhang, Xue Zhang, Qin Li Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-020-00430-1 ABSTRACT Abstract Cancer stem cells (CSCs) show a self-renewal capacity and differentiation potential that contribute to tumor progression and therapy resistance. However, the underlying processes are still unclear. Elucidation of the key hallmarks and resistance mechanisms of CSCs may help improve patient outcomes and reduce relapse by altering therapeutic regimens. Here, we reviewed the identification of CSCs, the intrinsic and extrinsic mechanisms of therapy resistance in CSCs, the signaling pathways of CSCs that mediate treatment failure, and potential CSC-targeting agents in various tumors from the clinical perspective. Targeting the mechanisms and pathways described here might contribute to further drug discovery and therapy. Subject terms: Cancer stem cells, Cancer therapy INTRODUCTION Therapy resistance is becoming a major problem in medicine; while patients initially respond to treatment, sustained administration frequently results in therapy resistance along with a poor prognosis. Both genetic and nongenetic mechanisms enable cancer cells to resist treatment.1 Traditionally, cancer is viewed as a homogenous mass of rapidly proliferating cells. Over the last decades, a more complex model, in which cancer tissue is composed of heterogeneous cell populations with a hierarchical organization has replaced the previous one-dimensional view. Cancer stem cells (CSCs) are on top of this hierarchical structure.2 Eppert and colleagues3 published their pioneering work showing that a defined subset of leukemia cells (CD38+CD34-) was solely responsible for propagating acute myeloid leukemia (AML). A decade later, Al-Hajj’s team showed that as few as 100 cells with a CD44+CD24- phenotype could form tumors in mice, whereas tens of thousands of cells with alternate phenotypes failed to form tumors.4 Many other teams have also found that only a few fractions of cancer cells can reform secondary tumors after transplantation into immunodeficient mice. This cluster of cells are commonly described using special terms such as CSCs, tumor propagating cells, tumor progenitor cells (TPCs) and cancer-initiating cells (CICs). In many adult tissues, stem cells (SCs) are responsible for tissue homeostasis and regeneration, and they can give rise to transit-amplifying (TA) cell populations.5 Similar to normal tissue SCs, CSCs show self-renewal and are defined by their ability to (i) generate a xenograft that histologically resembles the parent tumor from which it was derived, (ii) be serially transplanted in a xenograft assay thereby showing self-renewal (regenerate), and (iii) generate daughter cells that possess some proliferative capabilities but are unable to initiate or maintain the cancer because they lack intrinsic regenerative potential6 (Fig. 1). [Figure: Poor response to therapy due to CSCs. In heterogeneous tumors that contain CSCs, though non-CSCs are ablated, CSC will sustain tumor growth for its ability of self-renewing, then no long-term tumor recurrence or metastatic tumor will be observed] The mechanisms of therapy resistance in cancer can be categorized as intrinsic and acquired. Intrinsic mechanisms are due to preexisting factors of the cancer that are present prior to any treatment, thus rendering certain treatments useless. Acquired drug resistance develops during treatment. Accumulating evidence has shown that the expression of markers related to stemness is crucial for tumor maintenance and that these molecule also mediate resistance. In most cases, tumor recurrence is the result of a resistant CSC (intrinsic or acquired) in the primary tumor and its sphere formation7 and self-renewing abilities8 (Fig. 1). Based on the “seed and soil” theory, at a distant site, a resistant CSC can drive metastasis and then form a metastatic tumor9 (Fig. 1); thus, an increase in the CSC signature in tumors is associated with a worse prognosis.3 Based on the functional CSC concept, CSCs are naturally resistant to chemo- or radiotherapy, indicating they can survive after chemoradiotherapy and develop into a new cancer. However, understanding the properties of CSCs is the first step. The eventual goal is to investigate why CSCs can escape treatment, be retained, and form a new carcinoma. Identification of CSCs The classical definition of CSCs is a rare subpopulation of cells endowed with the capacity for self-renew and tumor-generating potential. Therefore, different methods have been developed and are currently exploited to isolate CSCs from patient-derived tumors or cancer cell lines in vitro. In this context, specific patterns of biomarkers that identify CSCs have been determined for some solid tumors such as CD44+CD24- for breast cancer (Table 1). However, increasing findings have showed that the previously defined CSC population is still heterogeneous, and thus, researchers must further enrich these cells by additional differentially expressed markers. [Table: Identification of cancer stem cells in human cancer] Isolation markers CSCs can be isolated through different biomarkers on the cell surface by fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS). Classical surface markers, such as CD133, CD44, epithelial cell adhesion molecule (EpCAM) and CD90 are extensively applied. However, some CSC surface markers are shared with normal stem cells. Therefore, multiple markers must be utilized for the accurate targeting of CSCs. CD133 CD133 is a membrane-bound pentaspan glycoprotein first identified in neuroepithelial SCs in mice and later found in human tissues.10 CD133 was used as a CSC marker in a series of tumors. In 2004, Singh and colleagues11 identified CD133 as a CSC marker in brain TICs because injection of as few as 100 CD133+ cells produced a tumor that could be serially transplanted and was a phenocopy of the patient’s original tumor, whereas injection of 105 CD133− cells engrafted but did not result in a tumor. Then, CD133 was identified as a CSC marker in hepatocellular carcinoma (HCC),12 glioblastoma,13 colon tumors7 and ovarian cancers (OCs).14 However, CD133 alone cannot always indicate the CSC phenotype. Researchers have thus focused on investigating combined signatures. CD133 combined with Nestin may be an optimal CSC-specific marker in glioma patients.15,16 The combination of CD133 and CD44 was used to define a novel HCC subpopulation. CD133+CD44high xenografts, but not CD133+CD44−/low, CD133−CD44high or CD133−CD44−/low xenografts, produced intrahepatic or lung metastasis in nude mice.17 Similarly, Naotsugu Haraguchi’s team showed that the CD133+CD44+ population may identify TICs in human colon cancer.18 In 2009, aldehyde dehydrogenase (ALDH) was reported to contribute to the stemness of the CD133+CD44+ fraction in colon tumors.19 Using ALDH in combination with CD133 to analyze OC cell lines, Ines A Silva observed greater growth in ALDH+CD133+ cells than ALDH+CD133− cells, suggesting a further enrichment of ovarian CSCs in ALDH+CD133+ cells.20 More recently, research showed that double-positive L1 cell adhesion molecule (L1CAM)+CD133+ cells displayed higher spherogenic and clonogenic properties than L1CAM−CD133− cells in OC and indicated radiotherapy resistance.21 CD44 CD44, a nonkinase transmembrane glycoprotein, is thought to play a role in CSCs.22 As mentioned previously, CD44 was first used as a CSC marker in breast cancer.4 Then CD44 was identified as a CSC marker in colorectal cancer (CRC),23,24 pancreatic cancer,25 OC,26 gastric cancer,27 and others. In CRC, a recent meta-analysis suggested that the combination of CD44 and CD133 indicated an approximately sevenfold increase in the tumorigenic potential, while CD133 alone indicated 1.45-foldchange, and CD44 alone indicated twofold increase.28 Moreover, the ability to engraft in vivo in immunodeficient mice was restricted to a minority subpopulation of EpCAMhigh/CD44+ epithelial cells in CRC;23 furthermore, ALDH combined with either CD44 or CD133 could increase the tumor-initiating